Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

The prevalence of obesity continues to remain high in the US making the demand for effective treatments even more urgent.

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best ...

Viatris Inc.'s volatile stock performance, CEO's strategic focus on growth, and promising pipeline highlight potential for ...

Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may ...